Making Medicines Affordable: A National Imperative (2018)
Chapter: Appendix D: Stakeholder Input
D
Stakeholder Input
RASHMI AGARWAL, U.S. Government Accountability Office
PETER BACH, Memorial Sloan Kettering Cancer Center
DAVID BEIER, Bay City Capital
ERNST BERNDT, Massachusetts Institute of Technology Sloan School of Management
GAIL CASSELL, Infectious Disease Research Institute; formerly, Eli Lilly and Company
RON COHEN, Acorda Therapeutics; Biotechnology Industry Organization
NITIN DAMLE (Co-Sponsor), American College of Physicians
GWEN DARIEN, National Patient Advocate Foundation
JOSEPH DIMASI, Tufts Center for the Study of Drug Development
AUTUMN EHNOW, Medicines360
MARIA FREIRE, Foundation for the National Institutes of Health; United Nations High-Level Panel on Access to Medicines
STEVEN GALSON, Amgen
ROBERT GALVIN, Equity Healthcare, Blackstone Group
JEREMY GREENE, Johns Hopkins University School of Medicine
KEVIN GRIMES, Stanford School of Medicine
RONALD HANSEN, University of Rochester Simon Business School
AARON KESSELHEIM, Brigham and Women’s Hospital
CHRISTOPHER KOLLER (Co-Sponsor), Milbank Memorial Fund
SHARON LEVINE, Kaiser Permanente Medical Group
FREDA LEWIS-HALL, Pfizer Inc.
FRANK LICHTENBERG, Columbia University
ANDREW LO, Massachusetts Institute of Technology Sloan School of Management
STACIE MAASS, American Pharmacists Association
STEVE MILLER, Express Scripts
JENNIFER MOORE, Institute for Medicaid Innovation
LARRY NORTON (Co-Sponsor), Breast Cancer Research Foundation
DAVID PARKINSON, Essa Pharmaceuticals
HAROLD PAZ, Aetna
STEVEN PEARSON, Institute for Clinical and Economic Review
GEORGE POSTE, Arizona State University
BRUCE RECTOR, Doctors for America
JOHN ROTHER, National Coalition on Health Care
DAVID SCHLEIFER, Public Agenda
KEVIN SCHULMAN, Duke University School of Medicine
SUSAN STUARD, Oregon Health & Science University
MASON TENAGLIA, QuintilesIMS Institute
ROY VAGELOS, Regeneron Pharmaceuticals, Inc.; formerly, Merck & Co., Inc.
CHRISTOPHER VIEHBACHER, Boston Pharmaceuticals; formerly, Sanofi
HAIME WORKIE, Financial Industry Regulatory Authority
